Charles River Laboratories International (CRL) Financials

$137.60 +1.35 (+0.99%)

Closing price 05/29/2025 03:59 PM Eastern

Extended Trading

$137.64 +0.03 (+0.03%)

As of 05/29/2025 06:15 PM Eastern

Annual Income Statements for Charles River Laboratories International

This table shows Charles River Laboratories International's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/28/2024	12/30/2023	12/31/2022	12/25/2021	12/26/2020	12/28/2019	12/29/2018	12/30/2017	12/31/2016	12/26/2015
Net Income / (Loss) Attributable to Common Shareholders	22	475	486	391	364	252	226	123	155	149
Consolidated Net Income / (Loss)	25	480	493	399	365	254	229	125	156	151
Net Income / (Loss) Continuing Operations	25	480	493	399	365	254	227	126	156	152
Total Pre-Tax Income	93	581	623	481	447	304	282	297	223	195
Total Operating Income	227	617	651	590	433	351	331	288	238	206
Total Gross Profit	1,332	1,503	1,463	1,335	1,074	958	840	701	644	531
Total Revenue	4,050	4,129	3,976	3,540	2,924	2,621	2,266	1,858	1,681	1,363
Operating Revenue	4,050	4,129	3,976	3,540	2,924	2,621	2,266	1,858	1,681	1,363
Total Cost of Revenue	2,718	2,627	2,513	2,206	1,850	1,663	1,426	1,157	1,037	832
Operating Cost of Revenue	2,718	2,627	2,513	2,206	1,850	1,663	1,426	1,157	1,037	832
Total Operating Expenses	1,104	885	812	745	641	607	509	413	406	325
Selling, General & Admin Expense	751	748	665	620	529	518	444	371	365	300
Amortization Expense	138	137	147	125	112	90	65	41	42	24
Impairment Charge	215	0.00	0.00	-	-	-	-	-	-	-
Total Other Income / (Expense), net	-134	-36	-28	-109	14	-47	-50	8.67	-15	-11
Interest Expense	126	137	59	74	86	61	64	30	28	15
Interest & Investment Income	8.58	5.20	0.78	0.65	0.83	1.52	0.81	0.69	1.31	1.04
Other Income / (Expense), net	-17	96	31	-36	100	12	13	38	12	3.01
Income Tax Expense	68	101	130	82	82	50	54	171	67	43
Preferred Stock Dividends Declared	12	0.00	0.00	-	-	-	-	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	3.09	5.75	6.38	7.86	1.00	2.04	2.35	2.09	1.60	1.77
Basic Earnings per Share	$0.20	$9.27	$9.57	$7.77	$7.35	$5.17	$4.72	$2.60	$3.29	$3.21
Weighted Average Basic Shares Outstanding	51.38M	51.23M	50.81M	50.29M	49.55M	48.73M	47.95M	47.48M	47.01M	46.50M
Diluted Earnings per Share	$0.20	$9.22	$9.48	$7.60	$7.20	$5.07	$4.62	$2.54	$3.23	$3.13
Weighted Average Diluted Shares Outstanding	51.63M	51.45M	51.30M	51.43M	50.61M	49.69M	49.02M	48.56M	47.96M	46.50M
Weighted Average Basic & Diluted Shares Outstanding	51.14M	51.35M	50.99M	50.49M	49.78M	48.96M	48M	47.40M	47.01M	46.50M

This table shows Charles River Laboratories International's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	9/24/2022
Net Income / (Loss) Attributable to Common Shareholders	25	-214	70	94	73	187	87	97	103	187	96
Consolidated Net Income / (Loss)	26	-214	70	94	74	189	88	99	104	189	98
Net Income / (Loss) Continuing Operations	26	-214	70	94	74	189	88	99	104	189	98
Total Pre-Tax Income	36	-217	91	120	99	209	113	129	131	245	123
Total Operating Income	75	-168	117	152	126	133	152	165	168	164	151
Total Gross Profit	318	284	349	354	345	364	362	399	378	399	370
Total Revenue	984	1,003	1,010	1,026	1,012	1,013	1,027	1,060	1,029	1,100	989
Operating Revenue	984	1,003	1,010	1,026	1,012	1,013	1,027	1,060	1,029	1,100	989
Total Cost of Revenue	666	718	661	672	667	649	665	661	652	701	619
Operating Cost of Revenue	666	718	661	672	667	649	665	661	652	701	619
Total Operating Expenses	243	452	232	202	219	231	210	234	210	235	219
Selling, General & Admin Expense	178	196	199	170	186	197	176	200	175	200	184
Amortization Expense	65	41	32	32	33	34	34	34	35	35	36
Total Other Income / (Expense), net	-39	-49	-26	-32	-27	76	-39	-36	-37	81	-28
Interest Expense	28	28	30	33	35	34	34	35	34	35	11
Interest & Investment Income	1.40	1.84	1.53	3.01	2.20	1.59	1.37	1.43	0.81	0.34	0.12
Other Income / (Expense), net	-12	-23	2.59	-2.24	5.83	108	-6.26	-2.66	-3.28	116	-17
Income Tax Expense	10	-3.04	21	25	25	20	25	29	27	56	25
Preferred Stock Dividends Declared	0.00	-	0.60	-	-	-	0.00	-	-	-	-
Net Income / (Loss) Attributable to Noncontrolling Interest	0.41	-8.27	0.64	3.97	6.75	1.87	0.63	2.42	0.82	1.70	1.14
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)	0.00	-	0.38	0.30	0.40	-	0.00	0.00	0.00	-	-
Basic Earnings per Share	$0.50	($4.20)	$1.34	$1.75	$1.31	$3.66	$1.70	$1.89	$2.02	$3.68	$1.90
Weighted Average Basic Shares Outstanding	50.68M	51.38M	51.39M	51.55M	51.44M	51.23M	51.28M	51.22M	51.10M	50.81M	50.87M
Diluted Earnings per Share	$0.50	($4.17)	$1.33	$1.74	$1.30	$3.63	$1.69	$1.89	$2.01	$3.66	$1.88
Weighted Average Diluted Shares Outstanding	50.85M	51.63M	51.58M	51.85M	51.84M	51.45M	51.61M	51.47M	51.43M	51.30M	51.28M
Weighted Average Basic & Diluted Shares Outstanding	49.12M	51.14M	51.14M	51.63M	51.51M	51.35M	51.30M	51.27M	51.18M	50.99M	50.88M

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/28/2024	12/30/2023	12/31/2022	12/25/2021	12/26/2020	12/28/2019	12/29/2018	12/30/2017	12/31/2016	12/26/2015
Net Change in Cash & Equivalents	-79	43	-5.10	13	-6.93	43	40	35	2.93	-30
Net Cash From Operating Activities	735	684	620	761	547	481	441	318	317	307
Net Cash From Continuing Operating Activities	735	684	620	761	547	481	441	318	317	307
Net Income / (Loss) Continuing Operations	25	480	493	399	365	254	227	126	156	152
Consolidated Net Income / (Loss)	25	480	493	399	365	254	229	125	156	151
Depreciation Expense	362	314	304	266	235	198	162	131	127	95
Non-Cash Adjustments To Reconcile Net Income	452	27	42	129	-18	34	75	19	60	29
Changes in Operating Assets and Liabilities, net	-104	-138	-219	-32	-36	-4.82	-23	43	-26	31
Net Cash From Investing Activities	-245	-563	-608	-1,438	-602	-682	-955	-73	-693	-328
Net Cash From Continuing Investing Activities	-245	-563	-608	-1,438	-602	-682	-955	-73	-693	-328
Purchase of Property, Plant & Equipment	-233	-319	-325	-229	-167	-141	-140	-82	-55	-63
Acquisitions	-5.48	-195	-283	-1,293	-419	-516	-825	-25	-648	-248
Purchase of Investments	-53	-54	-158	-46	-27	-22	-25	-46	-40	-34
Divestitures	0.00	0.00	163	123	0.00	0.00	-	72	0.00	0.00
Sale and/or Maturity of Investments	42	6.67	4.55	6.53	11	0.94	36	9.13	48	20
Other Investing Activities, net	4.55	-2.29	-9.35	0.26	-1.07	-3.89	-0.81	-0.52	3.69	-2.22
Net Cash From Financing Activities	-551	-86	-42	673	47	232	558	-208	381	-7.26
Net Cash From Continuing Financing Activities	-551	-86	-42	673	47	232	558	-208	381	-7.26
Repayment of Debt	-1,525	-856	-2,940	-6,281	-2,206	-3,143	-2,221	-377	-675	-422
Repurchase of Common Equity	-119	-24	-39	-41	-24	-18	-14	-107	-12	-117
Issuance of Debt	1,082	776	2,952	6,951	2,231	3,358	2,755	237	1,045	493
Other Financing Activities, net	12	18	-16	43	47	35	38	39	23	39
Effect of Exchange Rate Changes	-17	8.04	26	18	0.79	11	-	-	-	-

This table details how cash moves in and out of Charles River Laboratories International's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	9/24/2022
Net Change in Cash & Equivalents	26	-6.07	31	-158	54	119	-43	-0.11	-32	45	-11
Net Cash From Operating Activities	172	159	252	194	130	221	205	148	109	235	133
Net Cash From Continuing Operating Activities	172	159	252	194	130	221	205	148	109	235	133
Net Income / (Loss) Continuing Operations	26	-214	70	94	74	189	88	99	104	189	98
Consolidated Net Income / (Loss)	26	-214	70	94	74	189	88	99	104	189	98
Depreciation Expense	120	102	88	86	85	81	79	78	77	78	75
Non-Cash Adjustments To Reconcile Net Income	52	347	42	38	25	-58	44	8.08	33	-80	38
Changes in Operating Assets and Liabilities, net	-27	-76	52	-25	-55	9.77	-5.37	-37	-105	49	-77
Net Cash From Investing Activities	-45	-76	-21	-62	-86	-238	-80	-77	-169	44	-92
Net Cash From Continuing Investing Activities	-45	-76	-21	-62	-86	-238	-80	-77	-169	44	-92
Purchase of Property, Plant & Equipment	-59	-76	-39	-39	-79	-78	-66	-67	-107	-89	-72
Purchase of Investments	-5.30	-7.61	-9.73	-22	-14	-18	-14	-10	-13	-29	-21
Divestitures	17	-	-	-	-	-	-	-	-	-	-
Sale and/or Maturity of Investments	1.60	2.22	27	4.86	7.50	2.71	1.01	0.99	1.95	1.45	2.90
Other Investing Activities, net	0.10	4.91	0.01	-0.09	-0.28	-0.25	-0.99	-0.10	-0.96	-2.40	-2.17
Net Cash From Financing Activities	-105	-76	-208	-286	18	124	-163	-71	25	-249	-52
Net Cash From Continuing Financing Activities	-105	-76	-208	-286	18	124	-163	-71	25	-249	-52
Repayment of Debt	-149	-181	-343	-706	-295	-321	-218	-160	-157	-410	-657
Repurchase of Common Equity	-353	-0.12	-101	-8.91	-9.35	-0.14	-0.04	-4.97	-19	-0.16	-0.02
Issuance of Debt	416	105	236	440	301	443	51	89	193	154	618
Other Financing Activities, net	-19	0.77	0.78	-11	22	1.16	3.94	3.93	9.08	7.40	-13
Effect of Exchange Rate Changes	5.27	-13	7.70	-3.34	-8.39	13	-6.19	-0.16	1.67	15	-0.03

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/28/2024	12/30/2023	12/31/2022	12/25/2021	12/26/2020	12/28/2019	12/29/2018	12/30/2017	12/31/2016	12/26/2015
Total Assets	7,528	8,195	7,603	7,024	5,491	4,693	3,856	2,930	2,712	2,068
Total Current Assets	1,403	1,609	1,439	1,274	1,201	1,021	898	827	657	559
Cash & Equivalents	195	277	234	241	228	238	195	164	118	118
Accounts Receivable	721	780	752	643	618	514	472	430	364	270
Inventories, net	279	380	256	199	186	161	128	115	96	94
Prepaid Expenses	209	171	197	191	169	109	102	118	34	30
Plant, Property, & Equipment, net	1,604	1,640	1,466	1,291	0.00	1,044	933	782	756	678
Total Noncurrent Assets	4,521	4,947	4,698	4,459	4,290	2,627	2,025	1,321	1,299	831
Long-Term Investments	218	244	312	201	-	-	-	-	-	-
Goodwill	2,847	3,095	2,850	2,712	1,809	1,541	1,247	805	788	439
Intangible Assets	723	864	955	1,061	788	689	611	370	394	281
Noncurrent Deferred & Refundable Income Taxes	42	40	41	40	38	45	23	23	29	40
Other Noncurrent Operating Assets	691	703	540	444	1,477	213	144	124	88	72
Total Liabilities & Shareholders' Equity	7,528	8,195	7,603	7,024	5,491	4,693	3,856	2,930	2,712	2,068
Total Liabilities	4,020	4,536	4,579	4,432	3,347	3,026	2,518	1,866	1,858	1,303
Total Current Liabilities	994	1,055	1,092	1,033	840	710	558	464	430	312
Accounts Payable	140	169	206	198	122	111	66	78	68	37
Accrued Expenses	232	228	220	229	150	139	107	90	84	89
Current Deferred Revenue	248	242	264	220	208	172	145	118	128	81
Current Employee Benefit Liabilities	179	213	197	246	207	159	137	101	93	73
Other Current Liabilities	194	203	205	140	102	91	71	44	27	13
Total Noncurrent Liabilities	3,026	3,481	3,488	3,399	2,507	2,316	1,959	1,402	1,428	991
Long-Term Debt	2,240	2,647	2,708	2,664	1,930	1,850	1,637	1,114	1,208	846
Noncurrent Deferred & Payable Income Tax Liabilities	107	191	216	240	217	167	144	90	56	48
Other Noncurrent Operating Liabilities	679	642	565	496	361	299	179	195	159	89
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	41	57	42	53	25	29	19	17	15	28
Total Equity & Noncontrolling Interests	3,467	3,602	2,981	2,539	2,118	1,638	1,320	1,047	839	738
Total Preferred & Common Equity	3,462	3,597	2,976	2,535	2,115	1,635	1,317	1,045	837	733
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,462	3,597	2,976	2,535	2,115	1,635	1,317	1,045	837	733
Common Stock	1,967	1,906	1,805	1,719	1,628	1,532	1,448	2,561	2,478	2,399
Retained Earnings	1,812	1,887	1,433	981	625	280	42	289	165	11
Treasury Stock	0.00	0.00	0.00	0.00	0.00	0.00	-0.06	-1,660	-1,553	-1,541
Accumulated Other Comprehensive Income / (Loss)	-317	-196	-262	-165	-139	-178	-173	-145	-254	-136
Noncontrolling Interest	5.45	5.39	4.79	4.16	3.57	3.24	2.45	2.33	2.36	4.49

This table presents Charles River Laboratories International's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	9/24/2022
Total Assets	7,582	7,528	8,004	7,948	8,153	8,195	7,607	7,772	7,699	7,603	7,383
Total Current Assets	1,506	1,403	1,495	1,499	1,668	1,609	1,444	1,505	1,448	1,439	1,415
Cash & Equivalents	229	195	210	179	327	277	157	200	202	234	194
Accounts Receivable	757	721	754	762	787	780	799	801	788	752	771
Inventories, net	290	279	336	349	361	380	293	285	263	256	262
Prepaid Expenses	230	209	194	209	193	171	195	218	196	197	189
Plant, Property, & Equipment, net	1,587	1,604	1,640	1,614	1,619	1,640	1,525	1,530	1,494	1,466	1,381
Total Noncurrent Assets	4,489	4,521	4,869	4,835	4,866	4,947	4,637	4,738	4,757	4,698	4,587
Long-Term Investments	214	218	236	232	244	244	302	300	294	312	-
Goodwill	2,873	2,847	3,125	3,080	3,070	3,095	2,885	2,917	2,902	2,850	2,776
Intangible Assets	656	723	778	800	828	864	886	930	958	955	968
Noncurrent Deferred & Refundable Income Taxes	49	42	38	36	37	40	34	39	41	41	40
Other Noncurrent Operating Assets	697	691	692	687	688	703	530	553	562	540	803
Total Liabilities & Shareholders' Equity	7,582	7,528	8,004	7,948	8,153	8,195	7,607	7,772	7,699	7,603	7,383
Total Liabilities	4,341	4,020	4,176	4,175	4,449	4,536	4,256	4,472	4,543	4,579	4,711
Total Current Liabilities	1,051	994	1,012	948	955	1,055	994	1,008	981	1,092	1,014
Accounts Payable	149	140	136	133	130	169	136	140	120	206	182
Accrued Expenses	242	232	208	192	191	228	198	221	221	220	197
Current Deferred Revenue	250	248	252	247	256	242	250	257	262	264	251
Current Employee Benefit Liabilities	197	179	211	177	190	213	224	191	176	197	200
Other Current Liabilities	211	194	205	198	188	203	185	199	202	205	182
Total Noncurrent Liabilities	3,290	3,026	3,164	3,228	3,494	3,481	3,262	3,465	3,561	3,488	3,697
Long-Term Debt	2,511	2,240	2,327	2,409	2,660	2,647	2,514	2,678	2,744	2,708	2,937
Noncurrent Deferred & Payable Income Tax Liabilities	107	107	168	165	180	191	185	207	212	216	196
Other Noncurrent Operating Liabilities	672	679	670	653	653	642	563	579	605	565	564
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	42	41	41	46	58	57	40	42	43	42	39
Total Equity & Noncontrolling Interests	3,200	3,467	3,787	3,727	3,646	3,602	3,311	3,258	3,114	2,981	2,633
Total Preferred & Common Equity	3,194	3,462	3,782	3,723	3,640	3,597	3,306	3,252	3,109	2,976	2,627
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	3,194	3,462	3,782	3,723	3,640	3,597	3,306	3,252	3,109	2,976	2,627
Common Stock	1,979	1,967	1,972	1,957	1,940	1,906	1,878	1,851	1,831	1,805	1,781
Retained Earnings	1,838	1,812	2,123	2,054	1,960	1,887	1,720	1,633	1,536	1,433	1,280
Treasury Stock	-357	0.00	-120	-18	-9.35	0.00	-24	-24	-19	0.00	-38
Accumulated Other Comprehensive Income / (Loss)	-265	-317	-193	-270	-250	-196	-268	-208	-239	-262	-396
Noncontrolling Interest	5.78	5.45	4.85	4.29	5.72	5.39	4.77	5.85	5.29	4.79	5.89

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/28/2024	12/30/2023	12/31/2022	12/25/2021	12/26/2020	12/28/2019	12/29/2018	12/30/2017	12/31/2016	12/26/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-1.92%	3.86%	12.31%	21.08%	11.55%	15.67%	21.99%	10.48%	23.34%	5.06%
EBITDA Growth	-44.24%	4.22%	20.24%	6.76%	36.70%	10.88%	10.77%	21.60%	23.54%	6.20%
EBIT Growth	-70.42%	4.59%	23.02%	3.99%	46.57%	5.46%	5.70%	30.77%	19.03%	11.18%
NOPAT Growth	-87.89%	-0.90%	5.18%	38.42%	20.51%	9.75%	119.25%	-26.70%	3.56%	23.57%
Net Income Growth	-94.74%	-2.48%	23.51%	9.18%	43.79%	11.08%	82.32%	-19.77%	3.49%	17.85%
EPS Growth	-97.83%	-2.74%	24.74%	5.56%	42.01%	9.74%	81.89%	-21.36%	3.19%	17.67%
Operating Cash Flow Growth	7.41%	10.37%	-18.55%	39.19%	13.65%	9.02%	38.69%	0.37%	3.28%	21.70%
Free Cash Flow Firm Growth	669.25%	-163.25%	133.18%	-90.64%	-5.83%	56.87%	-1,096.99%	116.93%	-802.84%	-116.52%
Invested Capital Growth	-7.78%	11.57%	7.74%	23.57%	17.44%	17.99%	37.04%	3.67%	30.14%	14.53%
Revenue Q/Q Growth	-0.27%	-2.05%	5.15%	3.33%	3.54%	3.54%	5.74%	0.63%	7.20%	1.81%
EBITDA Q/Q Growth	-41.70%	-3.36%	13.18%	-2.88%	12.50%	9.31%	4.80%	0.79%	7.86%	2.72%
EBIT Q/Q Growth	-67.15%	-5.15%	18.11%	-5.24%	16.71%	11.53%	4.58%	1.77%	7.50%	5.50%
NOPAT Q/Q Growth	-85.83%	1.14%	-4.70%	8.82%	8.03%	-0.43%	83.08%	-39.64%	9.48%	3.81%
Net Income Q/Q Growth	-94.09%	-0.03%	11.12%	-1.08%	21.11%	8.69%	64.01%	-37.19%	8.97%	3.20%
EPS Q/Q Growth	-97.50%	-0.32%	11.66%	-1.81%	19.80%	8.57%	66.79%	-38.05%	9.12%	2.96%
Operating Cash Flow Q/Q Growth	-7.73%	-1.98%	0.90%	13.57%	-7.18%	9.25%	3.70%	1.79%	-0.72%	7.38%
Free Cash Flow Firm Q/Q Growth	283.81%	-117.44%	-47.29%	57.08%	-306.75%	-5.17%	13.23%	-66.00%	21.87%	-267.52%
Invested Capital Q/Q Growth	-6.53%	7.02%	-4.28%	-6.49%	5.31%	0.01%	-0.31%	-2.61%	-3.45%	-0.23%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	32.88%	36.39%	36.79%	37.70%	36.72%	36.56%	37.07%	37.73%	38.30%	38.96%
EBITDA Margin	14.14%	24.87%	24.78%	23.15%	26.25%	21.42%	22.35%	24.61%	22.36%	22.32%
Operating Margin	5.61%	14.95%	16.37%	16.66%	14.80%	13.40%	14.62%	15.52%	14.13%	15.14%
EBIT Margin	5.21%	17.26%	17.14%	15.65%	18.22%	13.87%	15.21%	17.55%	14.83%	15.36%
Profit (Net Income) Margin	0.62%	11.63%	12.39%	11.27%	12.49%	9.69%	10.09%	6.75%	9.30%	11.08%
Tax Burden Percent	27.16%	82.64%	79.07%	82.97%	81.70%	83.55%	81.20%	42.25%	70.14%	77.31%
Interest Burden Percent	44.17%	81.55%	91.41%	86.78%	83.93%	83.67%	81.73%	91.08%	89.41%	93.30%
Effective Tax Rate	72.84%	17.36%	20.93%	17.03%	18.30%	16.45%	19.34%	57.71%	29.98%	22.20%
Return on Invested Capital (ROIC)	1.11%	9.30%	10.30%	11.24%	9.81%	9.58%	11.00%	6.05%	9.51%	11.28%
ROIC Less NNEP Spread (ROIC-NNEP)	-0.73%	7.91%	9.29%	6.68%	10.50%	7.06%	7.86%	6.39%	8.45%	9.90%
Return on Net Nonoperating Assets (RNNOA)	-0.40%	5.08%	7.25%	5.60%	9.37%	7.33%	8.05%	7.03%	9.80%	9.28%
Return on Equity (ROE)	0.71%	14.38%	17.54%	16.84%	19.18%	16.91%	19.04%	13.08%	19.31%	20.56%
Cash Return on Invested Capital (CROIC)	9.21%	-1.64%	2.84%	-9.84%	-6.23%	-6.93%	-20.26%	2.45%	-16.68%	-2.27%
Operating Return on Assets (OROA)	2.68%	9.02%	9.32%	8.85%	10.46%	8.50%	10.16%	11.56%	10.43%	10.63%
Return on Assets (ROA)	0.32%	6.08%	6.74%	6.37%	7.17%	5.94%	6.74%	4.45%	6.54%	7.67%
Return on Common Equity (ROCE)	0.70%	14.14%	17.22%	16.54%	18.87%	16.61%	18.73%	12.84%	18.72%	19.65%
Return on Equity Simple (ROE_SIMPLE)	0.73%	13.36%	16.55%	15.73%	17.28%	15.54%	17.36%	12.00%	18.69%	20.61%
Net Operating Profit after Tax (NOPAT)	62	510	515	489	354	293	267	122	166	161
NOPAT Margin	1.52%	12.35%	12.95%	13.82%	12.09%	11.19%	11.80%	6.56%	9.89%	11.78%
Net Nonoperating Expense Percent (NNEP)	1.84%	1.39%	1.01%	4.56%	-0.69%	2.52%	3.14%	-0.33%	1.06%	1.38%
Return On Investment Capital (ROIC_SIMPLE)	1.08%	8.16%	9.05%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	67.12%	63.61%	63.21%	62.30%	63.28%	63.44%	62.93%	62.27%	61.70%	61.04%
SG&A Expenses to Revenue	18.54%	18.11%	16.73%	17.51%	18.09%	19.75%	19.59%	19.99%	21.69%	22.04%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	27.27%	21.44%	20.41%	21.04%	21.92%	23.16%	22.45%	22.21%	24.17%	23.81%
Earnings before Interest and Taxes (EBIT)	211	713	681	554	533	363	345	326	249	209
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	573	1,027	985	820	768	562	506	457	376	304
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.75	3.37	3.72	7.35	5.92	4.54	4.08	4.96	4.31	5.09
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	277.92
Price to Revenue (P/Rev)	2.35	2.94	2.79	5.26	4.28	2.83	2.37	2.79	2.14	2.74
Price to Earnings (P/E)	428.75	25.55	22.80	47.65	34.37	29.44	23.74	42.02	23.30	25.01
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.23%	3.91%	4.39%	2.10%	2.91%	3.40%	4.21%	2.38%	4.29%	4.00%
Enterprise Value to Invested Capital (EV/IC)	2.14	2.47	2.56	4.34	3.67	2.74	2.44	3.02	2.40	2.97
Enterprise Value to Revenue (EV/Rev)	2.81	3.47	3.34	5.91	4.89	3.47	3.03	3.33	2.82	3.31
Enterprise Value to EBITDA (EV/EBITDA)	19.90	13.94	13.49	25.51	18.63	16.21	13.56	13.53	12.61	14.82
Enterprise Value to EBIT (EV/EBIT)	54.04	20.08	19.51	37.75	26.85	25.04	19.92	18.97	19.01	21.54
Enterprise Value to NOPAT (EV/NOPAT)	184.51	28.06	25.83	42.73	40.45	31.02	25.69	50.72	28.50	28.09
Enterprise Value to Operating Cash Flow (EV/OCF)	15.51	20.93	21.46	27.48	26.17	18.93	15.57	19.44	14.96	14.70
Enterprise Value to Free Cash Flow (EV/FCFF)	22.25	0.00	93.50	0.00	0.00	0.00	0.00	125.19	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.64	0.72	0.90	1.03	0.92	1.13	1.25	1.08	1.45	1.13
Long-Term Debt to Equity	0.64	0.72	0.90	1.03	0.90	1.11	1.22	1.05	1.41	1.11
Financial Leverage	0.55	0.64	0.78	0.84	0.89	1.04	1.02	1.10	1.16	0.94
Leverage Ratio	2.19	2.36	2.60	2.64	2.67	2.85	2.82	2.94	2.95	2.68
Compound Leverage Factor	0.97	1.93	2.38	2.29	2.24	2.38	2.31	2.68	2.64	2.50
Debt to Total Capital	38.97%	41.98%	47.24%	50.68%	48.01%	53.12%	55.48%	51.84%	59.13%	52.99%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	1.22%	1.08%	1.05%	1.40%	1.31%	1.05%
Long-Term Debt to Total Capital	38.97%	41.98%	47.24%	50.68%	46.80%	52.03%	54.44%	50.43%	57.82%	51.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.81%	0.99%	0.82%	1.09%	0.70%	0.90%	0.70%	0.86%	0.81%	2.00%
Common Equity to Total Capital	60.22%	57.04%	51.93%	48.23%	51.28%	45.98%	43.82%	47.31%	40.06%	45.01%
Debt to EBITDA	3.91	2.58	2.75	3.25	2.58	3.36	3.29	2.50	3.28	2.84
Net Debt to EBITDA	3.19	2.07	2.19	2.71	2.28	2.94	2.91	2.15	2.97	2.45
Long-Term Debt to EBITDA	3.91	2.58	2.75	3.25	2.51	3.29	3.23	2.44	3.21	2.78
Debt to NOPAT	36.28	5.19	5.26	5.44	5.60	6.44	6.24	9.39	7.43	5.37
Net Debt to NOPAT	29.59	4.17	4.20	4.54	4.95	5.62	5.51	8.05	6.72	4.64
Long-Term Debt to NOPAT	36.28	5.19	5.26	5.44	5.46	6.30	6.12	9.14	7.26	5.27
Altman Z-Score	2.45	2.80	2.59	3.52	3.34	2.45	2.28	2.95	2.27	2.86
Noncontrolling Interest Sharing Ratio	1.52%	1.64%	1.86%	1.82%	1.60%	1.76%	1.66%	1.87%	3.06%	4.40%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.41	1.52	1.32	1.23	1.43	1.44	1.61	1.78	1.53	1.79
Quick Ratio	0.92	1.00	0.90	0.86	1.01	1.06	1.20	1.28	1.12	1.24
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	512	-90	142	-429	-225	-212	-492	49	-292	-32
Operating Cash Flow to CapEx	315.31%	214.71%	190.82%	332.56%	328.16%	342.27%	314.98%	385.87%	573.18%	485.10%
Free Cash Flow to Firm to Interest Expense	4.05	-0.66	2.40	-5.80	-2.60	-3.49	-7.72	1.66	-10.53	-2.14
Operating Cash Flow to Interest Expense	5.82	5.00	10.45	10.29	6.32	7.90	6.92	10.68	11.44	20.36
Operating Cash Flow Less CapEx to Interest Expense	3.97	2.67	4.97	7.20	4.40	5.59	4.72	7.91	9.44	16.16
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.52	0.52	0.54	0.57	0.57	0.61	0.67	0.66	0.70	0.69
Accounts Receivable Turnover	5.40	5.39	5.70	5.62	5.17	5.32	5.02	4.68	5.30	5.16
Inventory Turnover	8.25	8.26	11.05	11.46	10.68	11.53	11.74	10.97	10.95	9.11
Fixed Asset Turnover	2.50	2.66	2.88	0.00	0.00	2.65	2.64	2.42	2.35	2.01
Accounts Payable Turnover	17.58	14.02	12.44	13.76	15.82	18.71	19.79	15.81	19.73	23.61
Days Sales Outstanding (DSO)	67.65	67.74	64.04	64.99	70.64	68.67	72.66	78.01	68.83	70.69
Days Inventory Outstanding (DIO)	44.23	44.19	33.03	31.84	34.16	31.67	31.08	33.26	33.35	40.08
Days Payable Outstanding (DPO)	20.76	26.04	29.34	26.53	23.08	19.51	18.44	23.09	18.50	15.46
Cash Conversion Cycle (CCC)	91.12	85.89	67.74	70.30	81.72	80.83	85.30	88.18	83.67	95.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,335	5,786	5,186	4,813	3,895	3,317	2,811	2,051	1,979	1,520
Invested Capital Turnover	0.73	0.75	0.80	0.81	0.81	0.86	0.93	0.92	0.96	0.96
Increase / (Decrease) in Invested Capital	-450	600	373	918	578	506	760	73	458	193
Enterprise Value (EV)	11,393	14,315	13,296	20,910	14,301	9,102	6,867	6,184	4,740	4,511
Market Capitalization	9,520	12,127	11,086	18,631	12,521	7,420	5,373	5,184	3,606	3,734
Book Value per Share	$67.69	$70.12	$58.50	$50.23	$42.51	$33.47	$27.39	$22.07	$17.68	$15.72
Tangible Book Value per Share	($2.12)	($7.06)	($16.29)	($24.54)	($9.69)	($12.19)	($11.24)	($2.74)	($7.29)	$0.29
Total Capital	5,748	6,306	5,731	5,256	4,123	3,555	3,006	2,209	2,089	1,629
Total Debt	2,240	2,647	2,708	2,664	1,980	1,888	1,668	1,145	1,235	863
Total Long-Term Debt	2,240	2,647	2,708	2,664	1,930	1,850	1,637	1,114	1,208	846
Net Debt	1,827	2,127	2,162	2,221	1,751	1,650	1,473	981	1,117	745
Capital Expenditures (CapEx)	233	319	325	229	167	141	140	82	55	63
Debt-free, Cash-free Net Working Capital (DFCFNWC)	214	277	114	-0.30	183	112	176	230	137	147
Debt-free Net Working Capital (DFNWC)	409	554	347	241	412	350	371	394	255	265
Net Working Capital (NWC)	409	554	347	241	361	311	340	363	227	247
Net Nonoperating Expense (NNE)	36	30	22	91	-12	39	39	-3.53	9.96	9.52
Net Nonoperating Obligations (NNO)	1,827	2,127	2,162	2,221	1,751	1,650	1,473	987	1,125	755
Total Depreciation and Amortization (D&A)	362	314	304	266	235	198	162	131	127	95
Debt-free, Cash-free Net Working Capital to Revenue	5.29%	6.70%	2.86%	-0.01%	6.26%	4.26%	7.75%	12.40%	8.14%	10.75%
Debt-free Net Working Capital to Revenue	10.10%	13.41%	8.74%	6.81%	14.08%	13.34%	16.37%	21.22%	15.14%	19.40%
Net Working Capital to Revenue	10.10%	13.41%	8.74%	6.81%	12.36%	11.87%	14.99%	19.55%	13.51%	18.15%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.20	$9.27	$9.57	$7.77	$7.35	$5.17	$4.72	$2.60	$3.29	$3.21
Adjusted Weighted Average Basic Shares Outstanding	51.38M	51.23M	50.81M	50.29M	49.55M	48.73M	47.95M	47.43M	47.37M	46.72M
Adjusted Diluted Earnings per Share	$0.20	$9.22	$9.48	$7.60	$7.20	$5.07	$4.62	$2.54	$3.23	$3.13
Adjusted Weighted Average Diluted Shares Outstanding	51.63M	51.45M	51.30M	51.43M	50.61M	49.69M	49.02M	47.43M	47.37M	46.72M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$5.17	$4.72	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	51.14M	51.35M	50.99M	50.49M	49.78M	48.96M	48.23M	47.43M	47.37M	46.72M
Normalized Net Operating Profit after Tax (NOPAT)	310	510	515	489	354	293	267	202	166	161
Normalized NOPAT Margin	7.65%	12.35%	12.95%	13.82%	12.09%	11.19%	11.80%	10.86%	9.89%	11.78%
Pre Tax Income Margin	2.30%	14.08%	15.67%	13.58%	15.29%	11.60%	12.43%	15.99%	13.26%	14.33%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	1.67	5.21	11.49	7.50	6.16	5.97	5.40	10.95	9.00	13.90
NOPAT to Interest Expense	0.49	3.73	8.68	6.62	4.09	4.82	4.19	4.09	6.00	10.66
EBIT Less CapEx to Interest Expense	-0.18	2.88	6.02	4.40	4.24	3.66	3.21	8.18	7.00	9.70
NOPAT Less CapEx to Interest Expense	-1.36	1.40	3.20	3.53	2.16	2.51	2.00	1.33	4.01	6.46
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	471.22%	5.03%	7.85%	10.21%	6.56%	7.12%	6.05%	85.22%	7.85%	77.76%

This table displays calculated financial ratios and metrics derived from Charles River Laboratories International's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/29/2025	12/28/2024	9/28/2024	6/29/2024	3/30/2024	12/30/2023	9/30/2023	7/1/2023	4/1/2023	12/31/2022	9/24/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-2.71%	-1.08%	-1.64%	-3.19%	-1.73%	-7.85%	3.79%	8.92%	12.63%	21.52%	10.40%
EBITDA Growth	-15.82%	-127.49%	-7.10%	-1.86%	-10.14%	-10.01%	7.25%	7.10%	23.65%	47.41%	0.33%
EBIT Growth	-52.62%	-179.11%	-17.38%	-7.93%	-19.93%	-13.85%	8.10%	9.93%	37.00%	59.74%	-3.75%
NOPAT Growth	-43.33%	-197.54%	-23.44%	-6.29%	-28.85%	-4.85%	-1.31%	-11.42%	4.21%	-14.34%	-9.93%
Net Income Growth	-65.26%	-213.12%	-20.14%	-5.21%	-28.35%	-0.08%	-9.83%	-10.14%	9.17%	35.24%	-7.18%
EPS Growth	-61.54%	-214.88%	-21.30%	-7.94%	-35.32%	-0.82%	-10.11%	-11.27%	11.05%	37.08%	-6.47%
Operating Cash Flow Growth	32.19%	-27.87%	22.56%	30.66%	18.75%	-5.88%	54.73%	-0.90%	6.58%	2.40%	-24.01%
Free Cash Flow Firm Growth	283.23%	169.39%	-263.45%	-222.58%	-78.76%	-94.96%	186.05%	129.17%	83.95%	68.06%	88.55%
Invested Capital Growth	-8.36%	-7.78%	5.59%	5.36%	7.19%	11.57%	-0.21%	-0.27%	5.83%	7.74%	5.25%
Revenue Q/Q Growth	-1.83%	-0.71%	-1.59%	1.44%	-0.19%	-1.28%	-3.14%	2.97%	-6.41%	11.19%	1.65%
EBITDA Q/Q Growth	307.07%	-142.41%	-11.59%	8.44%	-32.38%	43.31%	-6.60%	-0.72%	-32.28%	70.80%	-6.73%
EBIT Q/Q Growth	132.80%	-258.66%	-19.69%	13.35%	-45.23%	65.70%	-10.50%	-1.42%	-41.07%	107.92%	-8.99%
NOPAT Q/Q Growth	145.75%	-229.77%	-24.29%	26.07%	-21.25%	1.86%	-7.33%	-4.28%	5.30%	5.66%	-16.82%
Net Income Q/Q Growth	112.11%	-404.07%	-25.43%	26.56%	-60.58%	114.67%	-11.49%	-4.34%	-45.03%	93.73%	-11.79%
EPS Q/Q Growth	111.99%	-413.53%	-23.56%	33.85%	-64.19%	114.79%	-10.58%	-5.97%	-45.08%	94.68%	-11.74%
Operating Cash Flow Q/Q Growth	7.74%	-36.71%	30.10%	49.00%	-41.21%	7.54%	38.70%	35.42%	-53.41%	76.80%	-11.17%
Free Cash Flow Firm Q/Q Growth	61.74%	257.12%	-21.63%	40.72%	38.75%	-470.09%	-8.79%	186.46%	33.20%	-63.34%	69.07%
Invested Capital Q/Q Growth	-0.49%	-6.53%	-1.09%	-0.39%	0.14%	7.02%	-1.31%	1.34%	4.24%	-4.28%	-1.37%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	32.28%	28.35%	34.56%	34.47%	34.09%	35.92%	35.25%	37.64%	36.69%	36.27%	37.43%
EBITDA Margin	18.58%	-8.81%	20.62%	22.95%	21.47%	31.69%	21.83%	22.64%	23.48%	32.45%	21.13%
Operating Margin	7.59%	-16.73%	11.63%	14.78%	12.45%	13.12%	14.76%	15.56%	16.31%	14.89%	15.26%
EBIT Margin	6.35%	-18.99%	11.88%	14.56%	13.03%	23.75%	14.15%	15.31%	15.99%	25.40%	13.58%
Profit (Net Income) Margin	2.63%	-21.32%	6.96%	9.19%	7.36%	18.64%	8.57%	9.38%	10.10%	17.19%	9.87%
Tax Burden Percent	71.93%	98.60%	77.04%	78.78%	75.23%	90.54%	77.98%	77.29%	79.33%	77.21%	79.29%
Interest Burden Percent	57.60%	113.87%	76.04%	80.08%	75.12%	86.72%	77.71%	79.28%	79.60%	87.67%	91.62%
Effective Tax Rate	28.07%	0.00%	22.96%	21.22%	24.77%	9.47%	22.02%	22.71%	20.67%	22.79%	20.71%
Return on Invested Capital (ROIC)	3.95%	-8.53%	6.55%	8.44%	6.88%	8.94%	8.97%	9.16%	10.07%	9.15%	8.66%
ROIC Less NNEP Spread (ROIC-NNEP)	2.62%	-13.40%	5.52%	7.23%	5.94%	12.14%	7.71%	8.04%	8.82%	12.00%	7.85%
Return on Net Nonoperating Assets (RNNOA)	1.57%	-7.39%	3.03%	4.27%	3.76%	7.79%	6.15%	6.67%	7.09%	9.37%	8.29%
Return on Equity (ROE)	5.52%	-15.92%	9.57%	12.71%	10.64%	16.73%	15.11%	15.84%	17.17%	18.52%	16.96%
Cash Return on Invested Capital (CROIC)	6.27%	9.21%	2.40%	3.02%	1.50%	-1.64%	9.53%	9.49%	4.28%	2.84%	5.11%
Operating Return on Assets (OROA)	3.24%	-9.78%	6.18%	7.55%	6.76%	12.41%	7.96%	8.36%	8.86%	13.81%	7.11%
Return on Assets (ROA)	1.34%	-10.98%	3.62%	4.77%	3.82%	9.75%	4.82%	5.12%	5.59%	9.35%	5.17%
Return on Common Equity (ROCE)	5.43%	-15.68%	9.45%	12.53%	10.46%	16.45%	14.89%	15.59%	16.84%	18.17%	16.68%
Return on Equity Simple (ROE_SIMPLE)	-0.73%	0.00%	11.32%	11.97%	12.39%	0.00%	14.53%	15.07%	16.13%	0.00%	16.88%
Net Operating Profit after Tax (NOPAT)	54	-117	90	119	95	120	118	127	133	126	120
NOPAT Margin	5.46%	-11.71%	8.96%	11.64%	9.37%	11.87%	11.51%	12.03%	12.94%	11.50%	12.10%
Net Nonoperating Expense Percent (NNEP)	1.34%	4.87%	1.02%	1.21%	0.94%	-3.20%	1.26%	1.13%	1.25%	-2.86%	0.81%
Return On Investment Capital (ROIC_SIMPLE)	0.94%	-2.06%	-	-	-	1.93%	-	-	-	2.22%	-
Cost of Revenue to Revenue	67.72%	71.65%	65.44%	65.53%	65.91%	64.08%	64.75%	62.36%	63.31%	63.73%	62.57%
SG&A Expenses to Revenue	18.07%	19.52%	19.73%	16.55%	18.42%	19.45%	17.15%	18.85%	16.99%	18.15%	18.57%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	24.70%	45.08%	22.94%	19.69%	21.64%	22.81%	20.49%	22.08%	20.38%	21.37%	22.17%
Earnings before Interest and Taxes (EBIT)	62	-190	120	149	132	241	145	162	165	279	134
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	183	-88	208	235	217	321	224	240	242	357	209
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.49	2.75	2.71	2.86	3.82	3.37	3.04	3.31	3.31	3.72	3.63
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	1.98	2.35	2.52	2.61	3.38	2.94	2.38	2.58	2.51	2.79	2.52
Price to Earnings (P/E)	0.00	428.75	24.16	24.10	31.27	25.55	21.16	22.23	20.73	22.80	21.86
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.23%	4.14%	4.15%	3.20%	3.91%	4.73%	4.50%	4.82%	4.39%	4.58%
Enterprise Value to Invested Capital (EV/IC)	1.90	2.14	2.13	2.20	2.77	2.47	2.25	2.37	2.33	2.56	2.28
Enterprise Value to Revenue (EV/Rev)	2.50	2.81	3.00	3.11	3.90	3.47	2.88	3.11	3.08	3.34	3.26
Enterprise Value to EBITDA (EV/EBITDA)	18.71	19.90	12.39	12.72	16.01	13.94	11.43	12.40	12.20	13.49	14.16
Enterprise Value to EBIT (EV/EBIT)	71.18	54.04	18.95	19.02	23.61	20.08	16.17	17.54	17.34	19.51	21.36
Enterprise Value to NOPAT (EV/NOPAT)	0.00	184.51	27.92	27.37	33.99	28.06	24.09	25.68	24.10	25.83	22.82
Enterprise Value to Operating Cash Flow (EV/OCF)	12.97	15.51	15.28	16.92	22.79	20.93	17.41	20.78	20.09	21.46	20.07
Enterprise Value to Free Cash Flow (EV/FCFF)	28.92	22.25	91.19	74.62	191.71	0.00	23.55	24.96	56.00	93.50	45.70
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.77	0.64	0.61	0.64	0.72	0.72	0.75	0.81	0.87	0.90	1.10
Long-Term Debt to Equity	0.77	0.64	0.61	0.64	0.72	0.72	0.75	0.81	0.87	0.90	1.10
Financial Leverage	0.60	0.55	0.55	0.59	0.63	0.64	0.80	0.83	0.80	0.78	1.06
Leverage Ratio	2.27	2.19	2.17	2.22	2.31	2.36	2.49	2.55	2.54	2.60	2.81
Compound Leverage Factor	1.31	2.50	1.65	1.78	1.74	2.05	1.93	2.02	2.02	2.28	2.58
Debt to Total Capital	43.65%	38.97%	37.80%	38.97%	41.80%	41.98%	42.87%	44.80%	46.50%	47.24%	52.38%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.04%
Long-Term Debt to Total Capital	43.65%	38.97%	37.80%	38.97%	41.80%	41.98%	42.87%	44.80%	46.50%	47.24%	52.34%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.82%	0.81%	0.74%	0.81%	1.00%	0.99%	0.76%	0.81%	0.82%	0.82%	0.80%
Common Equity to Total Capital	55.53%	60.22%	61.46%	60.21%	57.20%	57.04%	56.37%	54.39%	52.68%	51.93%	46.82%
Debt to EBITDA	4.66	3.91	2.37	2.41	2.65	2.58	2.37	2.56	2.66	2.75	3.38
Net Debt to EBITDA	3.84	3.19	1.91	2.00	2.08	2.07	1.93	2.08	2.18	2.19	3.15
Long-Term Debt to EBITDA	4.66	3.91	2.37	2.41	2.65	2.58	2.37	2.56	2.66	2.75	3.37
Debt to NOPAT	-18.40	36.28	5.34	5.20	5.63	5.19	4.98	5.30	5.25	5.26	5.44
Net Debt to NOPAT	-15.15	29.59	4.32	4.31	4.42	4.17	4.07	4.31	4.30	4.20	5.08
Long-Term Debt to NOPAT	-18.40	36.28	5.34	5.20	5.63	5.19	4.98	5.30	5.25	5.26	5.44
Altman Z-Score	2.07	2.28	2.47	2.55	2.87	2.61	2.42	2.42	2.31	2.42	2.09
Noncontrolling Interest Sharing Ratio	1.60%	1.52%	1.26%	1.39%	1.63%	1.64%	1.49%	1.56%	1.87%	1.86%	1.62%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.43	1.41	1.48	1.58	1.75	1.52	1.45	1.49	1.48	1.32	1.40
Quick Ratio	0.94	0.92	0.95	0.99	1.17	1.00	0.96	0.99	1.01	0.90	0.95
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	538	333	-212	-174	-294	-480	130	142	-164	-246	-151
Operating Cash Flow to CapEx	289.42%	210.75%	650.27%	490.14%	164.12%	282.09%	311.54%	219.82%	102.35%	263.70%	183.41%
Free Cash Flow to Firm to Interest Expense	19.31	11.79	-7.00	-5.32	-8.39	-14.30	3.84	4.06	-4.78	-7.07	-13.24
Operating Cash Flow to Interest Expense	6.16	5.64	8.31	5.91	3.71	6.59	6.09	4.23	3.18	6.75	11.67
Operating Cash Flow Less CapEx to Interest Expense	4.03	2.97	7.04	4.70	1.45	4.25	4.13	2.30	0.07	4.19	5.31
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.51	0.52	0.52	0.52	0.52	0.52	0.56	0.55	0.55	0.54	0.52
Accounts Receivable Turnover	5.21	5.40	5.23	5.22	5.22	5.39	5.37	5.40	5.51	5.70	5.28
Inventory Turnover	8.34	8.25	8.42	8.36	8.47	8.26	9.66	9.71	10.70	11.05	10.70
Fixed Asset Turnover	2.51	2.50	2.57	2.59	2.64	2.66	2.90	0.00	0.00	2.88	0.00
Accounts Payable Turnover	19.48	17.58	19.46	19.42	21.16	14.02	16.85	14.98	14.96	12.44	15.32
Days Sales Outstanding (DSO)	70.03	67.65	69.82	69.95	69.92	67.74	67.97	67.62	66.29	64.04	69.08
Days Inventory Outstanding (DIO)	43.74	44.23	43.34	43.63	43.10	44.19	37.78	37.58	34.11	33.03	34.12
Days Payable Outstanding (DPO)	18.74	20.76	18.76	18.80	17.25	26.04	21.67	24.37	24.40	29.34	23.83
Cash Conversion Cycle (CCC)	95.04	91.12	94.40	94.78	95.77	85.89	84.08	80.83	76.01	67.74	79.37
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	5,309	5,335	5,708	5,771	5,794	5,786	5,406	5,478	5,405	5,186	5,417
Invested Capital Turnover	0.72	0.73	0.73	0.73	0.73	0.75	0.78	0.76	0.78	0.80	0.72
Increase / (Decrease) in Invested Capital	-485	-450	302	294	389	600	-11	-15	298	373	270
Enterprise Value (EV)	10,070	11,393	12,165	12,690	16,052	14,315	12,148	12,987	12,587	13,296	12,328
Market Capitalization	7,955	9,520	10,239	10,641	13,899	12,127	10,048	10,761	10,290	11,086	9,537
Book Value per Share	$62.46	$67.69	$73.26	$72.27	$70.77	$70.12	$64.48	$63.53	$60.97	$58.50	$51.65
Tangible Book Value per Share	($6.55)	($2.12)	($2.34)	($3.05)	($5.01)	($7.06)	($9.07)	($11.62)	($14.73)	($16.29)	($21.96)
Total Capital	5,753	5,748	6,154	6,182	6,364	6,306	5,865	5,978	5,901	5,731	5,611
Total Debt	2,511	2,240	2,327	2,409	2,660	2,647	2,514	2,678	2,744	2,708	2,939
Total Long-Term Debt	2,511	2,240	2,327	2,409	2,660	2,647	2,514	2,678	2,744	2,708	2,937
Net Debt	2,067	1,827	1,880	1,998	2,090	2,127	2,055	2,178	2,248	2,162	2,745
Capital Expenditures (CapEx)	59	76	39	39	79	78	66	67	107	89	72
Debt-free, Cash-free Net Working Capital (DFCFNWC)	226	214	272	373	386	277	293	297	265	114	210
Debt-free Net Working Capital (DFNWC)	455	409	483	552	713	554	451	497	467	347	403
Net Working Capital (NWC)	455	409	483	552	713	554	451	497	467	347	401
Net Nonoperating Expense (NNE)	28	96	20	25	20	-69	30	28	29	-63	22
Net Nonoperating Obligations (NNO)	2,067	1,827	1,880	1,998	2,090	2,127	2,055	2,178	2,248	2,162	2,745
Total Depreciation and Amortization (D&A)	120	102	88	86	85	81	79	78	77	78	75
Debt-free, Cash-free Net Working Capital to Revenue	5.62%	5.29%	6.71%	9.14%	9.40%	6.70%	6.96%	7.10%	6.49%	2.86%	5.54%
Debt-free Net Working Capital to Revenue	11.32%	10.10%	11.88%	13.53%	17.35%	13.41%	10.69%	11.90%	11.41%	8.74%	10.66%
Net Working Capital to Revenue	11.32%	10.10%	11.88%	13.53%	17.35%	13.41%	10.69%	11.90%	11.41%	8.74%	10.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.50	($4.20)	$1.34	$1.75	$1.31	$3.66	$1.70	$1.89	$2.02	$3.68	$1.90
Adjusted Weighted Average Basic Shares Outstanding	50.68M	51.38M	51.39M	51.55M	51.44M	51.23M	51.28M	51.22M	51.10M	50.81M	50.87M
Adjusted Diluted Earnings per Share	$0.50	($4.17)	$1.33	$1.74	$1.30	$3.63	$1.69	$1.89	$2.01	$3.66	$1.88
Adjusted Weighted Average Diluted Shares Outstanding	50.85M	51.63M	51.58M	51.85M	51.84M	51.45M	51.61M	51.47M	51.43M	51.30M	51.28M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.12M	51.14M	51.14M	51.63M	51.51M	51.35M	51.30M	51.27M	51.18M	50.99M	50.88M
Normalized Net Operating Profit after Tax (NOPAT)	54	-117	90	119	95	120	118	127	133	126	120
Normalized NOPAT Margin	5.46%	-11.71%	8.96%	11.64%	9.37%	11.87%	11.51%	12.03%	12.94%	11.50%	12.10%
Pre Tax Income Margin	3.66%	-21.62%	9.04%	11.66%	9.79%	20.59%	10.99%	12.14%	12.73%	22.27%	12.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2.24	-6.74	3.96	4.56	3.77	7.17	4.30	4.63	4.79	8.03	11.81
NOPAT to Interest Expense	1.93	-4.16	2.99	3.65	2.71	3.59	3.50	3.64	3.87	3.64	10.52
EBIT Less CapEx to Interest Expense	0.11	-9.42	2.68	3.35	1.50	4.84	2.35	2.71	1.68	5.47	5.45
NOPAT Less CapEx to Interest Expense	-0.20	-6.84	1.71	2.44	0.45	1.25	1.55	1.72	0.77	1.08	4.16
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-1,985.83%	471.22%	27.85%	4.14%	3.21%	5.03%	5.03%	4.93%	4.72%	7.85%	8.74%

Frequently Asked Questions About Charles River Laboratories International's Financials

When does Charles River Laboratories International's fiscal year end?

According to the most recent income statement we have on file, Charles River Laboratories International's financial year ends in December. Their financial year 2024 ended on December 28, 2024.

How has Charles River Laboratories International's net income changed over the last 9 years?

Charles River Laboratories International's net income appears to be on an upward trend, with a most recent value of $25.29 million in 2024, falling from $151.09 million in 2015. The previous period was $480.37 million in 2023. Find out what analysts predict for Charles River Laboratories International in the coming months.

What is Charles River Laboratories International's operating income?

Charles River Laboratories International's total operating income in 2024 was $227.35 million, based on the following breakdown:

Total Gross Profit: $1.33 billion
Total Operating Expenses: $1.10 billion

How has Charles River Laboratories International revenue changed over the last 9 years?

Over the last 9 years, Charles River Laboratories International's total revenue changed from $1.36 billion in 2015 to $4.05 billion in 2024, a change of 197.1%.

How much debt does Charles River Laboratories International have?

Charles River Laboratories International's total liabilities were at $4.02 billion at the end of 2024, a 11.4% decrease from 2023, and a 208.6% increase since 2015.

How much cash does Charles River Laboratories International have?

In the past 9 years, Charles River Laboratories International's cash and equivalents has ranged from $117.63 million in 2016 to $276.77 million in 2023, and is currently $194.61 million as of their latest financial filing in 2024.

How has Charles River Laboratories International's book value per share changed over the last 9 years?

Over the last 9 years, Charles River Laboratories International's book value per share changed from 15.72 in 2015 to 67.69 in 2024, a change of 330.5%.

Related Companies

This page (NYSE:CRL) was last updated on 5/30/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Financials

Frequently Asked Questions About Charles River Laboratories International's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Charles River Laboratories International (CRL) Financials

Annual Income Statements for Charles River Laboratories International

Quarterly Income Statements for Charles River Laboratories International

Annual Cash Flow Statements for Charles River Laboratories International

Quarterly Cash Flow Statements for Charles River Laboratories International

Annual Balance Sheets for Charles River Laboratories International

Quarterly Balance Sheets for Charles River Laboratories International

Annual Metrics And Ratios for Charles River Laboratories International

Quarterly Metrics And Ratios for Charles River Laboratories International

Frequently Asked Questions About Charles River Laboratories International's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools